120 results
Page 3 of 6
6-K
EX-99.2
hciq5ld73l vsuds0os
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
83jdr
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
d3s5jc6ltdkgd359
27 Apr 22
Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
6:00am
6-K
EX-99.3
mvlbkhgmkomu 642xi
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.2
x3dvzy42p6pt zc57b
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
so9ogeactou8kf
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.6
jgol8140cmhgd csg961
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
v4hthf02oi9zww55k
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
xilkg7oucfe
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.1
1um8jzku4az4llxu0z
19 Jan 22
Jyseleca®▼ (Filgotinib) Licensed for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis In Great Britain
11:37am
6-K
EX-99.1
m6m7h5o8f03bvyp
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
6-K
EX-99.2
cd92 ntwrm
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
zg5ek3h
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
S-8
EX-4.1
zfixd bh97sl
26 Oct 21
Registration of securities for employees
4:07pm
6-K
EX-99.1
x2xqa
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
EX-99.1
fa62f9x0bz
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.1
7ig84jxw
31 Aug 21
Galapagos announces planned retirement of CEO
3:46pm
6-K
EX-99.2
w596 mzwrgykhoziw
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm